참고문헌
- Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012;33:2719-47. https://doi.org/10.1093/eurheartj/ehs253
- Park JM, Hong KS, Han SW, et al. Focused update on primary stroke prevention in patients with atrial fibrillation in Korean Clinical Practice Guidelines for Stroke. Korean J Stroke 2012;14:106-15. https://doi.org/10.5853/kjs.2012.14.3.106
- Albers GW, Diener HC, Frison L, et al. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA 2005;293:690-8. https://doi.org/10.1001/jama.293.6.690
- Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51. https://doi.org/10.1056/NEJMoa0905561
- Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-91. https://doi.org/10.1056/NEJMoa1009638
- Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011;364:806-17. https://doi.org/10.1056/NEJMoa1007432
- Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-92. https://doi.org/10.1056/NEJMoa1107039
- Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369:2093-104. https://doi.org/10.1056/NEJMoa1310907
- Clinical Research Center for Stroke. Primary prevention of stroke. In: Writing group of clinical practice guideline for stroke, editor. Clinical Practice Guideline for Stroke. 1st ed. Seoul: Clinical Research Center for Stroke; 2009. p.34-5.
- European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery, Camm AJ, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010;31:2369-429. https://doi.org/10.1093/eurheartj/ehq278
- Skanes AC, Healey JS, Cairns JA, et al. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can J Cardiol 2012;28:125-36. https://doi.org/10.1016/j.cjca.2012.01.021
- Ogawa S, Aonuma K, Tse HF, et al. The APHRS's 2013 statement on antithrombotic therapy of patients with nonvalvular atrial fibrillation. The APHRS's 2013 statement on antithrombotic therapy of patients with nonvalvular atrial fibrillation. J Arrhythm 2013;29:190-200. https://doi.org/10.1016/j.joa.2013.03.002
- January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation 2014;130:2071-104. https://doi.org/10.1161/CIR.0000000000000040
- Olesen JB, Lip GY, Hansen ML, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ 2011;342:d124. https://doi.org/10.1136/bmj.d124
- Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010;138:1093-100. https://doi.org/10.1378/chest.10-0134
- Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014;383:955-62. https://doi.org/10.1016/S0140-6736(13)62343-0
- Bang OY, Hong KS, Heo JH, et al. New oral anticoagulants may be particularly useful for Asian stroke patients. J Stroke 2014;16:73-80. https://doi.org/10.5853/jos.2014.16.2.73
- ACTIVE Investigators, Connolly SJ, Pogue J, et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009;360:2066-78. https://doi.org/10.1056/NEJMoa0901301
- ACTIVE Writing Group of the ACTIVE Investigators, Connolly S, Pogue J, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006;367:1903-12. https://doi.org/10.1016/S0140-6736(06)68845-4
- Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999;131:492-501.
- van Walraven C, Hart RG, Singer DE, et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA 2002;288:2441-8. https://doi.org/10.1001/jama.288.19.2441
- Mant J, Hobbs FD, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007;370:493-503. https://doi.org/10.1016/S0140-6736(07)61233-1
- Hori M, Connolly SJ, Zhu J, et al. Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation. Stroke 2013;44:1891-6. https://doi.org/10.1161/STROKEAHA.113.000990
- Wong KS, Hu DY, Oomman A, et al. Rivaroxaban for stroke prevention in East Asian patients from the ROCKET AF trial. Stroke 2014;45:1739-47. https://doi.org/10.1161/STROKEAHA.113.002968
- Shen AY, Yao JF, Brar SS, Jorgensen MB, Chen W. Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. J Am Coll Cardiol 2007;50:309-15. https://doi.org/10.1016/j.jacc.2007.01.098
피인용 문헌
- Young Male Patients with Atrial Fibrillation and CHA 2 DS 2 -VASc Score of 1 May Not Need Anticoagulants: A Nationwide Population-Based Study vol.11, pp.3, 2015, https://doi.org/10.1371/journal.pone.0151485
- Antithrombotic Therapy for Patients with Nonvalvular Atrial Fibrillation vol.90, pp.3, 2016, https://doi.org/10.3904/kjm.2016.90.3.189
- Risk of Ischemic Stroke in Patients With Non-Valvular Atrial Fibrillation Not Receiving Oral Anticoagulants ― Korean Nationwide Population-Based Study ― vol.81, pp.8, 2015, https://doi.org/10.1253/circj.cj-16-1267
- Proteinuria Detected by Urine Dipstick Test as a Risk Factor for Atrial Fibrillation: A Nationwide Population-Based Study vol.7, pp.None, 2015, https://doi.org/10.1038/s41598-017-06579-0
- Increased Risk of Atrial Fibrillation and Thromboembolism in Patients with Severe Psoriasis: a Nationwide Population-based Study vol.7, pp.None, 2015, https://doi.org/10.1038/s41598-017-10556-y
- Prevalence of Atrial Fibrillation in Korean Population vol.18, pp.4, 2015, https://doi.org/10.18501/arrhythmia.2017.030
- Antithrombotic Therapy Underutilization in Patients With Atrial Flutter vol.23, pp.3, 2015, https://doi.org/10.1177/1074248418757010
- The Use of Direct Oral Anticoagulants for Prevention of Stroke and Systemic Embolic Events in East Asian Patients with Nonvalvular Atrial Fibrillation vol.3, pp.2, 2015, https://doi.org/10.15212/cvia.2017.0033
- The treatment pattern and adherence to direct oral anticoagulants in patients with atrial fibrillation aged over 65 vol.14, pp.4, 2019, https://doi.org/10.1371/journal.pone.0214666
- Factors That Affect Time to Switch From Warfarin to a Direct Oral Anticoagulant After Change in the Reimbursement Criteria in Patients With Atrial Fibrillation vol.25, pp.1, 2020, https://doi.org/10.1177/1074248419868996
- Adherence to Anticoagulant Guideline for Atrial Fibrillation Improves Outcomes in Asian Population : The COOL-AF Registry vol.51, pp.6, 2015, https://doi.org/10.1161/strokeaha.120.029295